tiprankstipranks
Advertisement
Advertisement
BioAge Labs reports Q1 EPS (52c), consensus (63c)
PremiumThe FlyBioAge Labs reports Q1 EPS (52c), consensus (63c)
1M ago
BioAge Labs (BIOA): Phase 1 BGE-102 Data Reinforce Best-in-Class NLRP3 Potential and De-Risk 2026 Cardiovascular Phase 2, Supporting Buy Rating
Premium
Ratings
BioAge Labs (BIOA): Phase 1 BGE-102 Data Reinforce Best-in-Class NLRP3 Potential and De-Risk 2026 Cardiovascular Phase 2, Supporting Buy Rating
2M ago
BioAge Labs reports results for Phase 1 trial of BGE-102, to initiate Phase 2
Premium
The Fly
BioAge Labs reports results for Phase 1 trial of BGE-102, to initiate Phase 2
2M ago
BIOA Earnings this Week: How Will it Perform?
PremiumPre-EarningsBIOA Earnings this Week: How Will it Perform?
3M ago
BioAge Labs price target raised to $52 from $15 at Citi
Premium
The Fly
BioAge Labs price target raised to $52 from $15 at Citi
3M ago
BioAge Labs: Differentiated NLRP3 Inhibitor BGE-102 Positions Company for Best-in-Class Cardiometabolic Upside and Strategic M&A Appeal
Premium
Ratings
BioAge Labs: Differentiated NLRP3 Inhibitor BGE-102 Positions Company for Best-in-Class Cardiometabolic Upside and Strategic M&A Appeal
4M ago
BioAge Labs initiated with an Overweight at Piper Sandler
PremiumThe FlyBioAge Labs initiated with an Overweight at Piper Sandler
5M ago
BioAge Labs: De-Risked NLRP3 Program and 2026 Clinical Catalysts Underpin Overweight/Buy Rating
Premium
Ratings
BioAge Labs: De-Risked NLRP3 Program and 2026 Clinical Catalysts Underpin Overweight/Buy Rating
5M ago
BioAge Labs Announces Upsized Public Equity Offering
Premium
Company Announcements
BioAge Labs Announces Upsized Public Equity Offering
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100